Entrada Therapeutics Inc
TRDA5.970USD
+0.170+2.93%
Horário de mercado （ET）Cotações atrasadas em 15 min
226.52MValor de mercado
9.14P/L TTM
Mais detalhes de Entrada Therapeutics Inc Empresa
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.
Informações da empresa
Código da empresaTRDA
Nome da EmpresaEntrada Therapeutics Inc
Data de listagemOct 29, 2021
CEOMr. Dipal Doshi
Número de funcionários183
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 29
EndereçoOne Design Center Place
CidadeBOSTON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02210
Telefone18573051825
Sitehttps://www.entradatx.com/
Código da empresaTRDA
Data de listagemOct 29, 2021
CEOMr. Dipal Doshi
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Peter S. Kim, Ph.D.
Dr. Peter S. Kim, Ph.D.
Director
Director
104.33K
-10.60%
Dr. Natarajan Sethuraman, Ph.D.
Dr. Natarajan Sethuraman, Ph.D.
President of Research and Development
President of Research and Development
82.24K
-31.79%
Mr. Kory James Wentworth, CPA
Mr. Kory James Wentworth, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
31.84K
-27.89%
Mr. Nathan J. Dowden
Mr. Nathan J. Dowden
President, Chief Operating Officer
President, Chief Operating Officer
11.80K
-77.74%
Ms. Gina Chapman
Ms. Gina Chapman
Independent Director
Independent Director
--
--
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Dr. Kush M. Parmar, M.D., Ph.D.
Dr. Kush M. Parmar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Dipal Doshi
Mr. Dipal Doshi
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
Dr. Mahalakshmi (Maha) Radhakrishnan, M.D.
Dr. Mahalakshmi (Maha) Radhakrishnan, M.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Peter S. Kim, Ph.D.
Dr. Peter S. Kim, Ph.D.
Director
Director
104.33K
-10.60%
Dr. Natarajan Sethuraman, Ph.D.
Dr. Natarajan Sethuraman, Ph.D.
President of Research and Development
President of Research and Development
82.24K
-31.79%
Mr. Kory James Wentworth, CPA
Mr. Kory James Wentworth, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
31.84K
-27.89%
Mr. Nathan J. Dowden
Mr. Nathan J. Dowden
President, Chief Operating Officer
President, Chief Operating Officer
11.80K
-77.74%
Ms. Gina Chapman
Ms. Gina Chapman
Independent Director
Independent Director
--
--
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
FY2025Q1
FY2024
FY2023
FY2023Q2
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
20.56M
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 18 de jul
Atualizado em: sex, 18 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Baker Bros. Advisors LP
12.82%
MPM Capital Inc.
11.54%
5AM Ventures
11.21%
T. Rowe Price Associates, Inc.
7.11%
F. Hoffman La Roche, Ltd.
6.77%
Other
50.54%
Investidores
Investidores
Proporção
Baker Bros. Advisors LP
12.82%
MPM Capital Inc.
11.54%
5AM Ventures
11.21%
T. Rowe Price Associates, Inc.
7.11%
F. Hoffman La Roche, Ltd.
6.77%
Other
50.54%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
28.19%
Investment Advisor
23.69%
Hedge Fund
14.14%
Corporation
11.35%
Venture Capital
11.34%
Private Equity
2.01%
Individual Investor
1.01%
Research Firm
0.54%
Pension Fund
0.22%
Other
7.51%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
226
35.27M
92.92%
-1.95M
2025Q1
237
37.05M
97.63%
-2.01M
2024Q4
222
37.20M
98.96%
+761.72K
2024Q3
209
35.09M
95.11%
-779.91K
2024Q2
193
34.68M
94.55%
+2.42M
2024Q1
185
31.33M
93.34%
-1.07M
2023Q4
174
31.30M
93.83%
-1.07M
2023Q3
167
31.14M
93.63%
-973.86K
2023Q2
154
30.75M
92.59%
+53.89K
2023Q1
141
30.00M
92.19%
-903.00K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Baker Bros. Advisors LP
4.87M
12.82%
--
--
Mar 31, 2025
MPM Capital Inc.
4.38M
11.54%
--
--
Mar 31, 2025
5AM Ventures
4.31M
11.35%
-100.00K
-2.27%
Jun 30, 2025
T. Rowe Price Associates, Inc.
2.70M
7.11%
-167.02K
-5.83%
Mar 31, 2025
F. Hoffman La Roche, Ltd.
2.57M
6.77%
-175.00K
-6.38%
Dec 31, 2024
Janus Henderson Investors
2.12M
5.59%
+41.29K
+1.98%
Mar 31, 2025
Merck & Co Inc
1.74M
4.58%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.73M
4.56%
+55.00
+0.00%
Mar 31, 2025
The Vanguard Group, Inc.
1.57M
4.14%
+111.36K
+7.62%
Mar 31, 2025
Fidelity Management & Research Company LLC
1.24M
3.27%
-160.10K
-11.44%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Virtus LifeSci Biotech Clinical Trials ETF
0.77%
iShares Neuroscience and Healthcare ETF
0.36%
First Trust Dow Jones Select MicroCap Index Fund
0.27%
Harbor Human Capital Factor US Small Cap ETF
0.1%
Federated Hermes MDT Small Cap Core ETF
0.05%
iShares Micro-Cap ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.03%
WisdomTree US SmallCap Fund
0.03%
Avantis US Small Cap Equity ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
Ver Mais
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.77%
iShares Neuroscience and Healthcare ETF
Proporção0.36%
First Trust Dow Jones Select MicroCap Index Fund
Proporção0.27%
Harbor Human Capital Factor US Small Cap ETF
Proporção0.1%
Federated Hermes MDT Small Cap Core ETF
Proporção0.05%
iShares Micro-Cap ETF
Proporção0.04%
ProShares Ultra Nasdaq Biotechnology
Proporção0.03%
WisdomTree US SmallCap Fund
Proporção0.03%
Avantis US Small Cap Equity ETF
Proporção0.03%
Invesco Nasdaq Biotechnology ETF
Proporção0.03%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
